Source:http://linkedlifedata.com/resource/pubmed/id/11791010
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-1-15
|
pubmed:abstractText |
The area of vulnerability (AOV) to ventricular fibrillation (VF) induction by high-voltage shocks has been proposed as a measure of vulnerability to VF. Biphasic shocks spanning the T wave and ranging between 50 V and the upper limit of vulnerability (ULV) to VF were delivered before and after terikalant (1 mg/kg) and barium (1.1 mg/kg load followed by 0.05-0.10 mg/kg/min maintenance) or vehicle in dogs. The AOV decreased by 34% and 28% (p < 0.01) after terikalant and barium (n = 8 dogs each), respectively. Mean ULV, defibrillation threshold (DFT), and ventricular vulnerability period (VVP) decreased by 16%, 23%, and 31% (p < 0.01), respectively, after terikalant, and by 25%, 17% (p < 0.01), and 13% (p = 0.08), respectively, after barium. Vehicle (n = 14) did not significantly alter any of these variables. The ULV was correlated with the DFT before and after terikalant (r = 0.78, p < 0.01) and barium (r = 0.83, p < 0.01). Potassium channel blockers of the current reduce the ability to induce VF; this effect may be related to the anti-fibrillatory action of class III anti-arrhythmic drugs and their ability to decrease DFT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Arrhythmia Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Barium Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Chlorides,
http://linkedlifedata.com/resource/pubmed/chemical/Chromans,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/barium chloride,
http://linkedlifedata.com/resource/pubmed/chemical/terikalant
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0160-2446
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
242-50
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11791010-Action Potentials,
pubmed-meshheading:11791010-Animals,
pubmed-meshheading:11791010-Anti-Arrhythmia Agents,
pubmed-meshheading:11791010-Barium Compounds,
pubmed-meshheading:11791010-Chlorides,
pubmed-meshheading:11791010-Chromans,
pubmed-meshheading:11791010-Dogs,
pubmed-meshheading:11791010-Electric Countershock,
pubmed-meshheading:11791010-Electrocardiography,
pubmed-meshheading:11791010-Female,
pubmed-meshheading:11791010-Infusions, Intravenous,
pubmed-meshheading:11791010-Male,
pubmed-meshheading:11791010-Piperidines,
pubmed-meshheading:11791010-Ventricular Fibrillation,
pubmed-meshheading:11791010-Ventricular Function
|
pubmed:year |
2002
|
pubmed:articleTitle |
Terikalant and barium decrease the area of vulnerability to ventricular fibrillation induction by T-wave shocks.
|
pubmed:affiliation |
Division of Cardiology, Department of Medicine, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|